STK17A: A Potential Drug Target and Biomarker (G9263)

Target Name: STK17A

NCBI ID: G9263

STK17A

STK17A: A Potential Drug Target and Biomarker

Stk17a (Serine/threonine kinase 17a) is a protein that is expressed in various tissues of the body, including the brain, pancreas, and muscle. It plays a crucial role in the regulation of cell signaling pathways, which are essential for the development and maintenance of tissues and organs. Unfortunately, stk17a has also been implicated in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a result, it has become an attractive target for drug development. In this article, we will discuss stk17a as a potential drug target and biomarker.

Potential Drug Target

Stk17a has been shown to play a role in several signaling pathways that are involved in the development and progression of cancer. For example, stk17a has been shown to be involved in the regulation of the PI3K/Akt signaling pathway, which is known to be a key driver of cancer cell growth and survival. Additionally, stk17a has been shown to be involved in the regulation of the TGF-β signaling pathway, which is involved in the development of many diseases, including cancer.

Stk17a has also been shown to play a role in the regulation of the NF-kappa-B signaling pathway, which is involved in the regulation of inflammation and immune responses. The NF-kappa-B signaling pathway is known to be involved in the development of autoimmune diseases, including rheumatoid arthritis, lupus, and multiple sclerosis.

Biomarker

Stk17a has also been shown to be involved in the regulation of several biomarkers that are involved in the diagnosis and treatment of cancer. For example, stk17a has been shown to play a role in the regulation of the Mucin 1 (MUC1) gene, which is known to be involved in the regulation of cell signaling pathways and has been implicated in the development of many diseases, including cancer.

In addition, stk17a has been shown to play a role in the regulation of the Integrin 伪6 (ITGA6) gene, which is involved in the regulation of cell adhesion and has been implicated in the development of many diseases, including cancer.

Conclusion

In conclusion, stk17a is a protein that has been shown to play a role in several signaling pathways that are involved in the development and progression of cancer. As a result, stk17a has become an attractive target for drug development. The potential drug targets for stk17a include the regulation of the PI3K/Akt, TGF-β, and NF-kappa-B signaling pathways, as well as the regulation of Mucin 1 and Integrin 伪6 genes. Further research is needed to fully understand the role of stk17a in the development and progression of cancer, as well as its potential as a biomarker for the diagnosis and treatment of cancer.

Protein Name: Serine/threonine Kinase 17a

Functions: Acts as a positive regulator of apoptosis. Also acts as a regulator of cellular reactive oxygen species

The "STK17A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about STK17A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets